Miss Loren Waters
Senior Technician
School of Biosciences
Publication
2025
- Fdel, A. M. et al. 2025. Oxidative stress-responsive 1 kinase catalytic activity promotes triple negative breast cancer oncogenic potential. ACS pharmacology & translational science (10.1021/acsptsci.4c00603)
- Baldwin, A. G. et al. 2025. Discovery of MDI-114215: A potent and selective LIMK inhibitor to treat fragile X syndrome. Journal of Medicinal Chemistry 68(1), pp. 719-752. (10.1021/acs.jmedchem.4c02694)
- Baldwin, A. et al. 2025. Discovery of MDI-114215: A potent and selective LIMK inhibitor to treat Fragile X Syndrome. Journal of Medicinal Chemistry 68(1), pp. 719-752. (10.1021/acs.jmedchem.4c02694)
2022
- Collins, R. et al. 2022. Comparative analysis of small-molecule limk1/2 inhibitors: chemical synthesis, biochemistry, and cellular activity. Journal of Medicinal Chemistry (10.1021/acs.jmedchem.2c00751)
Articles
- Fdel, A. M. et al. 2025. Oxidative stress-responsive 1 kinase catalytic activity promotes triple negative breast cancer oncogenic potential. ACS pharmacology & translational science (10.1021/acsptsci.4c00603)
- Baldwin, A. G. et al. 2025. Discovery of MDI-114215: A potent and selective LIMK inhibitor to treat fragile X syndrome. Journal of Medicinal Chemistry 68(1), pp. 719-752. (10.1021/acs.jmedchem.4c02694)
- Baldwin, A. et al. 2025. Discovery of MDI-114215: A potent and selective LIMK inhibitor to treat Fragile X Syndrome. Journal of Medicinal Chemistry 68(1), pp. 719-752. (10.1021/acs.jmedchem.4c02694)
- Collins, R. et al. 2022. Comparative analysis of small-molecule limk1/2 inhibitors: chemical synthesis, biochemistry, and cellular activity. Journal of Medicinal Chemistry (10.1021/acs.jmedchem.2c00751)